Meeting
2016 ASCO Annual Meeting
Response to ado-trastuzumab emtansine according to RANO criteria in central nervous system metastases of HER2 positive breast cancers.
Authors
Audrey Mailliez
Centre Oscar Lambret, Lille, France
Audrey Mailliez , Edwina Girard , Thomas Boulanger , Claire Giraud , Jacques Bonneterre , Emilie Le Rhun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 605)
DOI
10.1200/JCO.2016.34.15_suppl.605
Abstract #
605
Poster Bd #
93
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2011 ASCO Annual Meeting
Survival after brain metastases in Asian patients with HER2+ breast cancer.
First Author: Y. S. Yap
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer